 This is a single-dose, open-labeled, non-randomized, two-period study of Cysteamine Bitartrate Delayed-release Capsules RP103 and Cystagon in up to 10 patients male or female with nephropathic cystinosis under fasting conditions. It will involve a 4 night check-in to a clinical research center. 